Compare ICCC & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICCC | PSTV |
|---|---|---|
| Founded | 1982 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.5M | 61.1M |
| IPO Year | 1987 | N/A |
| Metric | ICCC | PSTV |
|---|---|---|
| Price | $4.90 | $0.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 18.4K | ★ 5.6M |
| Earning Date | 11-13-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $27,769,304.00 | $5,258,000.00 |
| Revenue This Year | N/A | $9.91 |
| Revenue Next Year | N/A | $1.06 |
| P/E Ratio | $18.59 | ★ N/A |
| Revenue Growth | ★ 16.49 | N/A |
| 52 Week Low | $3.75 | $0.16 |
| 52 Week High | $7.60 | $2.31 |
| Indicator | ICCC | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 57.26 |
| Support Level | $4.52 | $0.48 |
| Resistance Level | $5.36 | $0.63 |
| Average True Range (ATR) | 0.29 | 0.05 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 25.33 | 86.96 |
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).